Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

AbbVie was once a division of the leading medical device company, Abbott Laboratories. The drugmaker started trading on the market in 2013, and since then, it has delivered market-beating returns.

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Shares in chipmaker Advanced Micro Devices (AMD) had also slumped in after-hours trading, falling nearly 9% before market open on Wednesday. While AMD (AMD) delivered strong fourth quarter ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...